Medicinal Usage of Cannabis and Cannabinoids

<p>Preface</p> <p>I. Setting the scene and introductory chapters</p> <p>1. How medical cannabis may influence the future of medicine<br>Martha Rosenthal</p> <p>2. Medical cannabis and cannabinoids: how best to extract components from plant material <br>Roberta Costi</p> <p>3. Medicinal usage of cannabis and its impact on mental health among cancer patients and survivors <br>Nicolas Hernandez Ortega, Ye Chen, Jessica Y. Islam, Diane Rodriguez, Marlene Camacho-Rivera and Denise Christina Vidot</p> <p>4. Cannabis sativa as a traditional phytomedicine: a new narrative covering different countries <br>Md Nasir Ahmed, Tridib Paul, Md. Nur Kabidul Azam, Rownak Jahan and Mohammed Rahmatullah</p> <p>5. Medical use of cannabis in the middle east <br>Bader Hamza Shirah, Mohammed Ahmed and Ruba Saleh</p> <p>6. What medicinal cannabis is used for: a focus on Canada <br>Dean T. Eurich, Cerina Lee and Jason Dyck</p> <p>7. New York perspectives of medical cannabis laboratory analysis<br>Lingyun Li, Stacey Chmura, Christopher Judd and Bryan C. Duffy</p> <p>8. Potential roles of epigenetic memory on the quality of clonal cannabis plants: Content and profile of secondary metabolites<br>Mohsen Hesami and Max Jones</p> <p>9. Aberrant use of medicinal cannabis: theoretical and empirical considerations <br>Daniel Feingold</p> <p>10. Profile of older users of medical cannabis and cannabinoids<br>Joshua Brown</p> <p>11. Use of cannabidiol oil by caregivers: a focus on Alzheimer's disease<br>Magdalena Leszko</p> <p>12. Medicinal use of cannabis: adverse events as a balanced perspective<br>Giada Crescioli, Valentina Maggini, Fabio Firenzuoli, Alfredo Vannacci and Niccolo Lombardi</p> <p>II. Physiological aspects and metabolic aspects</p> <p>13. Physiopathology and use of cannabinoids for fibrotic diseases <br>Carmen del Rio and E. Munoz</p> <p>14. Cannabinoids in inflammation and atherosclerosis <br>Leonor Thomson, Edward Moreira-Bahnson and Bruno Musetti</p> <p>15. Targeting the CB(2) receptors and other endocannabinoid elements to delay disease progression in cardiovascular diseases<br>Shreesh Ojha</p> <p>16. BMI in cannabis users: regulation, mechanisms and public health impact <br>Thomas Clark</p> <p>III. Neurological, psychological and behavioural aspects</p> <p>17. Neuroprotection by cannabis related products, cannabidiol and cannabigerol, and associated mechanisms of action<br>Carolina Echeverry Sr., Jimena Fagetti, Miguel Reyes-Parada and Cecilia Scorza</p> <p>18. Cannabis terpenes as neuroprotective agents: a focus on alpha-bisabolol<br>John Staton Laws, Srijan Shrestha and Scott D. Smid</p> <p>19. Cannabidiol in medicinal usage of stress: modelling investigations into cocaine<br>M. Julia García-Fuster and Olga Valverde</p> <p>20. Medicinal cannabis and neurocognition impairment<br>Caroline MacCallum, April Christiansen, Lindsay Lo, Carly Pistawka, Michael Boivin and Melissa Snider-Adler</p> <p>21. Genetic models of audiogenic seizures: what they are and how cannabinoids and Cannabis-derived compounds can be used to alleviate their symptoms - an updated narrative<br>Norberto Garcia-Cairasco</p> <p>22. Addressing the validity of cannabinoid therapy as an option for the treatment of substance use disorder<br>Rose Chesworth, Erin McLemon and Tim Karl</p> <p>IV. Pharmacological and cellular aspects</p> <p>23. Cannabidiolic acid (CBDA), features and profiles: anti-hyperalgesic effects <br>G. Singh, Katja Linher-Melville and Raphael Mechoulam</p> <p>24. Cannabis-drug interactions: implications for medicinal cannabis use <br>Fran Gengo, Anna Mattle and Christopher Ralyea</p> <p>25. Cannabinoid receptor subtype 2 (CB2R): features and targets for medical applications <br>Marialessandra Contino, Carmen Abate, Nicola Antonio Colabufo, Francesco Leonetti and Angela Stefanachi</p> <p>26. Medical use of cannabidiol and impact on cancer cell viability <br>Kent E. Chair and Wesley Raup-Konsavage</p> <p>27. Anti-inflammatory and antioxidant and immunomodulatory effects of phytocannabinoid β‑caryophyllene: A mechanistic overview<br>Vafa Baradaran Rahimi, Arghavan Memarzia and Prof. Vahid Reza Askari</p> <p>V. Symptom Control and Medicinal Uses</p> <p>28. Cancer patients and providers: Attitudes and beliefs of cannabis and cannabinoids use as a treatment <br>Kimberson Tanco</p> <p>29. CBD (cannabidiol) use in breast cancer chemotherapy<br>Ana I. Torres-Suarez, Ana Isabel Fraguas-Sánchez and Ana Fernández-Carballido</p> <p>30. Sleep: cannabis and cannabinoids use <br>Eric Murillo-Rodríguez</p> <p>31. Cannabis and cannabis related products and their uses in aiding sexual health of men and women　<br>Lynnette Nathalie Lyzwinski</p> <p>32. Symptom control in palliative care settings: The role of cannabis-based medicines <br>Maximillian Stevenson and Leah Sera</p> <p>33. Cannabidiol (CBD) Use in Fragile X Spectrum Disorders<br>Devon Johnson and Randi J. Hagerman</p> <p>34. Hempseed (Cannabis sativa) and ameliorative effects in hypercholesterolemia <br>NAVEEN KAUSHAL</p> <p>35. Benzodiazepines and cannabis use<br>Chad Alexander Purcell</p> <p>36. Features of (+)-trans-cannabidiol-2-hydroxy pentyland applications to disease: a focus on usage in diabetic nephropathy <br>E. Munoz, Matthias Winkler, Marcus Goetz and Isabel Gonzalez Mariscal</p> <p>37. Medical use of cannabis: applications to Tourette syndrome<br>Kirsten R. Müller-Vahl and Natalia Szejko</p> <p>38. Cannabinoids and their use in chronic non-cancer pain: a new narrative review <br>Stanley Sau-Ching Wong and Chi Wai Cheung</p> <p>39. Endometriosis: features and potential role of medical cannabis<br>Mike Armour and Justin Sinclair</p> <p>40. Cannabis usage for Crohn's disease and ulcerative colitis: a narrative<br>Joseph Feuerstein and Rajsavi Anand</p> <p>41. Medical cannabis and use in migraine<br>Jessica Jiang and Alasdair M. Barr</p> <p>42. Cannabidiol (CBD ) and potential in medicinal use in rheumatoid arthritis <br>Torsten Lowin</p> <p>43. Role of Cannabinoids in Glaucoma: Lowering Intraocular Pressure or Neuroprotection<br>Ujendra Kumar, Sneha Singh and Rishi Somvanshi</p> <p>44. Medicinal potential of anandamide as a representative endocannabinoid and its effect at the cellular level in skin<br>Adrianna Maria Piasek and Anna Sobiepanek</p> <p>VI. Resources</p> <p>45. Medical Cannabis and Resources<br>Rajkumar Rajendram</p>